



Biotech Daily

Tuesday October 12, 2021

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ORTHOCELL UP 5%; PRESCIENT DOWN 10%**
- * **ALCIDION SIGNS \$630k QUEEN'S HOSPITAL BURTON DEAL**
- * **IMRICOR: 'OVERSUBSCRIBED' PLAN RAISES \$1m; TOTAL \$17.5m**
- * **IMRICOR ICMR FOR HUNGARY'S SEMMELWEIS UNIVERSITY**
- * **ANTERIS APPOINTS IQVIA, CRF FOR DURAVR FEASIBILITY STUDY**
- * **CSL: 26% OPPOSE \$10m PAUL PERREAULT 'PERFORMANCE' SHARES**
- * **ANTEO 100% DIRECTORS' FEE POOL HIKE AGM**
- * **NEUROTECH REQUESTS 'PATENT LODGEMENT' TRADING HALT**
- * **ONCOSIL APPOINTS PROF RICKY SHARMA DIRECTOR**

MARKET REPORT

The Australian stock market fell 0.26 percent on Tuesday October 12, 2021, with the ASX200 down 19.1 points to 7,280.7 points. Eleven of the Biotech Daily Top 40 stocks were up, 21 fell and eight traded unchanged.

Orthocell was the best, up 2.5 cents or 4.9 percent to 53.5 cents, with 233,986 shares traded, followed by Antisense up 4.65 percent to 22.5 cents with 629,077 shares traded. Osprey climbed 3.9 percent; Nova Eye and Starpharma rose more than two percent; CSL, Pro Medicus, Proteomics and Resonance were up more than one percent; with Cynata, Paradigm and Telix up by less than one percent.

Prescient led the falls, down 2.5 cents or 10.2 percent to 22 cents, with 5.6 million shares traded.

Genetic Signatures lost 7.4 percent; Compumedics was down six percent; Neuren shed 5.2 percent; Actinogen and Volpara fell more than four percent; Dimerix, Impedimed and Pharmaxis were down more than three percent; Clinuvel, Next Science, Patrys and Polynovo shed more than two percent; Avita, Immutep, Kazia, Medical Developments, Mesoblast, Nanosonics and Opthea were down more than one percent; with Cochlear, Resmed and Universal Biosensors down by less than one percent.

[ALCIDION](#)

Alcidion says it has a \$630,000 three-year agreement to supply England's Queen's Hospital Burton with its Extramed Inpatient Flow Manager software.

Alcidion said the software was designed to enable staff to make decisions "based on real-time visibility of patient flow".

The company said it was first contract since it acquired Extramed, a provider of patient flow management systems to nine UK NHS Trusts (BD: Apr 15, 2021).

Alcidion said that Queen's Hospital Burton was part of the University Hospitals of Derby and Burton National Health Service Foundation Trust, which was one of the UK's largest.

The company said that both hospitals were existing users of its Patienttrack system.

Alcidion was unchanged at 35 cents with 1.1 million shares traded.

[IMRICOR MEDICAL SYSTEMS](#)

Imricor says it has raised \$1,000,000 in a share purchase plan at \$1.00 per Chess depository instrument (CDIs) that was "144 percent oversubscribed".

Imricor said that it had applications for \$2,443,000 in shares, and applications would be scaled back by 40.93 percent.

Last month, the company said that it raised \$16.5 million in a placement of CDIs at \$1.00 each (BD: Sep 8, 2021).

Imricor was up 10.5 cents or 9.25 percent to \$1.24.

[IMRICOR MEDICAL SYSTEMS](#)

Imricor says the Budapest-based Semmelweis University will be the eleventh centre use its Interventional Cardiac Magnetic Resonance imaging products.

Imricor said that Semmelweis University's Heart and Vascular Centre intends to implement the ICMR system in an existing cardiac magnetic resonance suite, with procedures to begin by the end of 2021.

[ANTERIS TECHNOLOGIES](#)

Anteris says it has appointed Iqvia and the Cardiac Research Foundation for a US Food and Drug Administration feasibility study of its Duravr trans-catheter heart valve.

Anteris said that the Durham, North Carolina-based Iqvia and the New York-based Cardiac Research Foundation would assist with the a single-arm, multi-centre study of Duravr's safety and feasibility in an unstated number of patients with severe aortic stenosis.

The company said that Iqvia would be responsible for clinical data monitoring, project and site management, data management and safety, with CRF providing laboratory services for the study, including echo computed tomography and the independent clinical events committee.

Anteris said the primary endpoint would be the durability and calcification at 30 days after the implant, with a 10-year, long-term follow-up.

The company said that the study was "an important milestone in the Duravr clinical development program as it will provide valuable clinical data to support the company's pursuit of regulatory approvals in multiple geographies".

Anteris said it had appointed the Minneapolis Minnesota-based investment bank Piper Sandler & Co as its mergers and acquisitions adviser.

Anteris was up seven cents or 0.9 percent to \$8.20.

CSL

CSL says that 25.7 percent of votes at its annual general meeting opposed \$9.8 million in “performance” shares for chief executive officer Paul Perreault.

In September, CSL said it intended to grant Mr Perreault up to 31,640 performance share units worth \$US7,214,120 (\$A9,803,490) (BD: Sep 3, 2021).

Today, the company said that 69,268,886 votes (25.73%) opposed Mr Perreault’s performance shares with 199,988,149 votes (74.27%) in favor.

Previously, opposition to Mr Perreault’s rights has ranged from 8.35 to 27.25 percent (BD: Oct 15, 2014; Oct 15, 2015; Oct 12, 2016; Oct 18, 2017; Oct 18, 2018, Oct 17, 2019).

Today, CSL said that the remuneration report was passed with 238,824,538 votes (88.60%) in favor, with 30,725,278 (11.40%) against, while the election of directors Dr Brian McNamee, Prof Andrew Cuthbertson, Alice Watkins and Prof Duncan Maskell, and approval of the proportional takeover provisions, passed easily.

CSL was up \$5.18 cents or 1.8 percent to \$292.68 with 779,369 shares traded.

ANTEOTECH

Anteo says its annual general meeting will vote to increase the total fee pool payable to non-executive directors by 100 percent from \$250,000 to \$500,000 a year.

Anteo said the increase was to “bring the aggregate into line with board fees for comparable companies that prevail in 2021” and allow for additional directors.

The company said the meeting would vote on the remuneration report, the re-election of directors Jack Hamilton, Glenda McLoughlin and Dr Katherine Woodthorpe, the employee incentive plan, the prior issue of shares and fee options, and adoption of its constitution.

Anteo fell one cent or 4.4 percent to 21.5 cents with 3.4 million shares traded.

NEUROTECH

Neurotech says it has requested a trading halt pending “an announcement regarding the lodgement of a material patent”.

Trading will resume on October 14, 2021, or on an earlier announcement.

Neurotech last traded at 5.1 cents.

ONCOSIL MEDICAL

Oncosil says it has appointed Prof Ricky Sharma as a non-executive director, effective from November 1, 2021.

Oncosil said that Prof Sharma was currently Varian’s clinical affairs head and was previously a University of Oxford associate professor, an honorary consultant at Oxford University Hospitals, and led a research team at University College London.

The company said Prof Sharma had more than 200 publications in peer reviewed scientific journals, and was an “authority on the translation of radiobiology”.

Oncosil said that Prof Sharma held a Bachelor of Medicine and a Bachelor of Surgery from England’s University of Cambridge.

Oncosil was unchanged at 4.6 cents.